Allergy Therapeutics (#AGY) – revenue slightly down, gross cash also slightly down to £12.8m

Allergy Therapeutics – further loan funding “successfully extended its cash runway”… but not for long!

‘Integrated commercial biotechnology company specialising in allergy vaccines’ Allergy Therapeutics (AGY) has announced “lenders have agreed to provide a further £5m from the existing amended loan facility… There remains a further £12.5m of uncommitted funding available under the amended loan facility”. So what of a current share price response down approaching 9% to 4.25p?

Allergy Therapeutics (#AGY) – “further £5m from the existing amended loan facility”, though only extends ‘cash runway’ to “late September”

Allergy Therapeutics – “half-year trading update”, to soon require further funding again!

Previously writing on allergy vaccines company Allergy Therapeutics (AGY), in August with the shares down towards 2.5p I concluded very significant funding to be needed quite swiftly and it not in a good negotiating position. So what of now, with the shares having most recently closed at 2.45p, an update on its half-year?

Allergy Therapeutics (#AGY) – H1 revenue -16%, currently anticipates further funding will be required during Q4

Allergy Therapeutics (#AGY) – cash runway now “towards the end of January”, funding discussions with certain major shareholders “well advanced”

Allergy Therapeutics (#AGY) – notes funding discussions “continuing positively” but “expects to require additional funding by the end of December”

Allergy Therapeutics (#AGY) – 34.91% open offer take-up, underwriting though means overall total approx. £40.75m equity raise

Allergy Therapeutics – “trading update”, boding adversely for funding “discussions”?

Although down from approaching 20p a year ago, shares in Allergy Therapeutics (AGY) had recently recovered from below 1p to around 3p. What about them currently down towards 2.5p on the back of a trading update?

Allergy Therapeutics – results publication means shares suspension lifted…and the shares slump…

Previously writing on Allergy Therapeutics (AGY), towards the end of last year as the shares fell from 11.375p I wrote audit delay and how’s the position in the current dire funding climate?, concluding in the dire funding climate to continue to avoid. The shares are today back from suspension as results are published but, with the funding climate still dire, how’s that financial position now?

Allergy Therapeutics (#AGY) – publishes delayed results to lift shares suspension but admits “need for additional near-term funding”

Allergy Therapeutics – audit delay and how’s the position in the current dire funding climate?

In July I noted on Allergy Therapeutics (AGY) with the shares down to 17p that brokerage finnCap argued “substantial potential upside as key value inflection points are reached over the next 18 months”, but with there also clear risks, including financial, in reaching them and a still £109.5 million market cap, at least before the upcoming results detail, I avoided. So what of today an “Annual Report and Accounts Delayed”-titled announcement?

Allergy Therapeutics (#AGY) – shares to be suspended due to audit delay, though also in discussions for required “significant additional near-term funding”!

Allergy Therapeutics (#AGY) – NED Scott Leinenweber “has resigned… with immediate effect”

Allergy Therapeutics (#AGY) – timeline to resume UK manufacturing, but currently expect unable to use NatWest revolving credit facility

Allergy Therapeutics – argues “significant clinical progress”, so why the further share price fall?

Allergy Therapeutics (AGY) has issued a trading update for its year ended 30th June 2022 emphasising “effective cost controls implemented alongside the group's significant clinical progress” and “in 2023, sales are expected to return to their previous near double-digit growth levels”. So what of a current share price response to 17p, approaching 7% lower?

Allergy Therapeutics (#AGY) – FY revenue down noting “streamlined portfolio”, upcoming cost increases

Allergy Therapeutics (#AGY) – placing to raise up to £10.6m at 26.5p

Despite Posting a Loss, Allergy Therapeutics is Not to Be Sneezed at

Hello Share Puzzlers. Thank goodness the hay fever season is over. I no longer suffer, having moved to the seaside, but the horror of a blocked conk and streaming eyes remains. You may have noticed that allergies seem to be on the rise. At least the number of folk who complain about them is.

Allergy Therapeutics (#AGY) says patient enrolement complete for Phase 2 trial of PQBirch204 drug